Amazon. ‘Nuff said.

According to a report by CNBC, Sandoz “does not expect Amazon to have a major impact on its business.” Wait, what? Fine, we’ll back up. Amazon is still sniffing around the pharma world. This time, it’s talking with generic drug giants, including Mylan and Sandoz. While the specific topics of conversation remain unclear, the smart money is on wholesale / distribution, right? What do you think is happing in the “war rooms” at McKesson, Cardinal Health, and other leading distributors? How does an industry defend against a cash-flush company that doesn’t seem to worry about profitability? That’s why InsightCity is no longer considering Cardinal Health as an acquisition target. Yep. That’s why.